Catalyst Outcomes
The most recent resolved FDA decisions and trial readouts with a clear result or a move of 15% or more. Upcoming decisions are on the FDA decisions page; how our predictions scored is on the track record.
November 2026
- Nov 6EVAX conference presentation — Positive+9%
- Nov 6JSPR Other — Positive+20%
- Nov 5IVA conference presentation — Negative-6%
- Nov 5IMUX conference presentation — Negative-8%
- Nov 5CRIS regulatory event — Negative-23%
- Nov 5VYGR Acquisition — Negative-8%
- Nov 5DRTS Other — Negative-5%
- Nov 5PCVX Phase 3 readout — Negative-6%
- Nov 4GNTA Other — Negative-29%
- Nov 3RMTI Acquisition — Positive+17%
- Nov 2TLSA Phase 2 readout — Negative-16%
- Nov 2ENLV Phase 2 readout — Negative-21%
- Nov 2TOVX Acquisition — Positive+6%
- Nov 2KPTI Acquisition — Negative-83%
October 2026
- Oct 30INO PDUFA decision — Negative-22%
- Oct 30ANVS Other — Positive+11%
- Oct 30PTHS Acquisition — Negative-43%
- Oct 30PTCT regulatory event — Negative-7%
- Oct 29NRSN Data Readout — Negative-10%
- Oct 27NANO Acquisition — Negative-7%
- Oct 26SNTI Acquisition — Negative-11%
- Oct 23ZNTL conference presentation — Negative-8%
- Oct 23LNAI Other — Negative-38%
- Oct 23BOLT Acquisition — Positive+50%
- Oct 23BKHA Other — Positive+26%
- Oct 23CYDY Data Readout — Positive+8%
- Oct 20UNCY regulatory event — Positive+8%
- Oct 20INDP Other — Positive+8%
- Oct 19VVOS Acquisition — Positive+8%
- Oct 19SLN Acquisition — Positive+126%
- Oct 16CRIS regulatory event — Negative-20%
- Oct 15MIRM Phase 3 readout — Negative-7%
- Oct 15KZIA Phase 2 readout — Positive+9%
- Oct 15ABOS Phase 2 readout — Negative-91%
- Oct 14FVNNR Acquisition — Negative-6%
- Oct 13TCRT Acquisition — Positive+189%
- Oct 13VRXA Phase 2 readout — Positive+5%
- Oct 12FLNA conference presentation — Negative-6%
- Oct 9HEPA Acquisition — Negative-8%
- Oct 8ARGX Phase 3 readout — Negative-12%
- Oct 6BYSI Acquisition — Negative-13%
- Oct 6RGEN Acquisition — Negative-8%
- Oct 5MRNA Phase 2 readout — Positive+7%
- Oct 5PCVX Phase 3 readout — Positive+31%
- Oct 5GMAB Phase 3 readout — Positive+11%
- Oct 5ADIA Acquisition — Negative-9%
- Oct 2QGEN Acquisition — Positive+6%
- Oct 2CNTB conference presentation — Negative-5%
- Oct 1ARGX Phase 3 readout — Positive+16%
- Oct 1IONS PDUFA decision — Negative-5%
- Oct 1BAYRY Phase 2 readout — Negative-6%
September 2026
- Sep 30TLSA Phase 2 readout — Positive+6%
- Sep 29LXEO Acquisition — Positive+9%
- Sep 29LIMN Other — Negative-8%
- Sep 28KOD Phase 3 readout — Positive+178%
- Sep 25CLDI Other — Negative-6%
- Sep 23TRAX regulatory event — Negative-11%
- Sep 22MRNA Phase 2 readout — Positive+6%
- Sep 21TLPPF Acquisition — Negative-11%
- Sep 15NVSEF Phase 2 readout — Positive+5%
- Sep 15NAMS Phase 2 readout — Negative-5%
- Sep 15DSGN Phase 2 readout — Negative-10%
- Sep 15ZURA Phase 2 readout — Negative-5%
- Sep 15AVIR Phase 3 readout — Negative-6%
- Sep 10ATALF conference presentation — Negative-20%
- Sep 10BHVN regulatory event — Negative-15%
- Sep 9CMPS Data Readout — Positive+8%
- Sep 9TYRA Data Readout — Negative-18%
- Sep 9TYRA Phase 2 readout — Negative-18%
- Sep 8ROIV Phase 2 readout — Positive+19%
- Sep 8INBX Phase 2 readout — Negative-6%
- Sep 3RNXT Data Readout — Negative-6%
- Sep 3NYXH Data Readout — Positive+17%
August 2026
- Aug 31KPTI NDA filing — Positive+10%
- Aug 28SHPH Other — Negative-9%
- Aug 28JUNS Other — Negative-15%
- Aug 24BIIB PDUFA decision — Negative-8%
- Aug 20EXOZ conference presentation — Positive+10%
- Aug 20MRNA Data Readout — Negative-24%
- Aug 19ETST Acquisition — Positive+22%
- Aug 19MRK Phase 3 readout — Positive+13%
- Aug 17ARGX Phase 3 readout — Positive+16%
- Aug 15BIVI Phase 2 readout — Negative-34%
- Aug 15KPTI Phase 3 readout — Negative-73%
- Aug 12NTHI Phase 2 readout — Negative-20%
- Aug 12NTHI Data Readout — Negative-20%
- Aug 12MRK Phase 3 readout — Positive+13%
- Aug 5HELP Data Readout — Positive+13%
July 2026
- Jul 31KPTI Phase 3 readout — Negative-73%
- Jul 30AARD regulatory event — Positive+20%
- Jul 30MRNA Phase 3 readout — Positive+6%
- Jul 27AZN Phase 3 readout — Negative-6%
- Jul 24LSTA Acquisition — Negative-21%
- Jul 22INCY Phase 2 readout — Negative-6%
- Jul 17CELC PDUFA decision — Positive+7%
- Jul 13QTTB Data Readout — Positive+91%
- Jul 12BIIB conference presentation — Negative-8%
- Jul 9IONS Phase 3 readout — Negative-24%
- Jul 8CMMB Acquisition — Negative-29%
- Jul 7AZN Phase 3 readout — Negative-6%
- Jul 1ALMS Phase 2 readout — Negative-5%
- Jul 1LLY regulatory event — Positive+7%
June 2026
- Jun 30EDSA Phase 2 readout — Positive+6%
- Jun 30MBRX Data Readout — Positive+11%
- Jun 30CRIS Trial Start — Positive+18%
- Jun 30CGTX Phase 2 readout — Positive+6%
- Jun 29TVRD Phase 2 readout — Positive+27%
- Jun 26HELP Data Readout — Positive+8%
- Jun 23ARGX conference presentation — Negative-6%
- Jun 22CLRB Phase 2 readout — Positive+12%
- Jun 17ICCM regulatory event — Positive+200%
- Jun 17OCUL conference presentation — Positive+8%
- Jun 17PTCT regulatory event — Positive+7%
- Jun 16IMDX Data Readout — Negative-7%
- Jun 15CODX Phase 2 readout — Negative-12%
- Jun 15RVMD Phase 3 readout — Positive+41%
- Jun 15MOLN Phase 2 readout — Negative-6%
- Jun 15ZBIO Phase 2 readout — Negative-6%
- Jun 15CYTK Phase 3 readout — Positive+17%
- Jun 15INCY Phase 2 readout — Negative-6%
- Jun 9RARE PDUFA decision — Positive+6%
- Jun 8BMEA conference presentation — Negative-9%
- Jun 4ZBIO Data Readout — Positive+6%
- Jun 4MPLT Phase 2 readout — Positive+6%
- Jun 1MOLN Phase 3 readout — Negative-6%
- Jun 1ARDX Phase 3 readout — Negative-5%
- Jun 1JBIO Phase 1 readout — Negative-12%
- Jun 1JBIO conference presentation — Negative-12%
- Jun 1KURA conference presentation — Negative-11%
- Jun 1OCS Phase 3 readout — Negative-23%
May 2026
- May 31VRTX Phase 3 readout — Positive+8%
- May 26KURA Data Readout — Negative-7%
- May 20GH PDUFA decision — Positive+17%
- May 18REGN Phase 2 readout — Negative-10%
- May 18DSGN Phase 1 readout — Negative-26%
- May 18QNCX Phase 2 readout — Negative-13%
- May 15CODX Phase 3 readout — Negative-21%
- May 15TNGX Phase 2 readout — Negative-17%
- May 15NMRA Phase 3 readout — Negative-7%
- May 15VSTM PDUFA decision — Negative-8%
- May 15SBFM Phase 2 readout — Negative-39%
- May 15VNRX conference presentation — Negative-9%
- May 15CODX Phase 2 readout — Negative-21%
- May 14RGNX Phase 3 readout — Negative-38%
- May 13KMDA regulatory event — Negative-7%
- May 12OLMA Data Readout — Negative-6%
- May 12REPL PDUFA decision — Positive+9%
- May 6RGNX Data Readout — Negative-38%
- May 5CRL Other — Positive+8%
April 2026
- Apr 30ANRO Phase 2 readout — Positive+6%